Abstract
Background: Venous thromboembolism (VTE) may be the earliest sign of cancer. Risk factors associated with the presence of an occult cancer in patients with a first acute unprovoked VTE are unknown. We sought to assess the risk factors predictive of occult cancer detection in patients with a first unprovoked symptomatic VTE.
Methods:Post-hoc, pre-defined analyses of the multicenter open-label randomized controlled trial - Screening for Occult Malignancy in Patients with Idiopathic Venous Thromboembolism (SOME) trial (Carrier M et al. N Engl J Med 2015). The trial compared comprehensive computed tomography (cCT) of the abdomen and pelvis in addition to limited occult-cancer screening (complete history and examination, basic laboratory testing, chest radiography, and breast, cervical and prostate cancer screening) with limited occult-cancer screening alone in patients with a first unprovoked episode of VTE. Cox proportional hazard models were used to analyze the effect of specific risk factors on the outcome of occult cancer within 12 months of a diagnosis of unprovoked VTE. Multivariable analysis was performed using Cox proportional hazard models that included all variables that achieved a p value of < 0.20 in univariate analyses.
Results: A total of 854 patients were randomized to limited occult cancer screening only, or limited occult cancer screening in combination with a cCT. The mean age was 54 years and 67.4% were males. A total of 33 (3.9%; 95% C.I. 2.8-5.4) patients received a new diagnosis of cancer at 12 months follow-up. Age ≥ 60 years, compared to age < 60 years, was a predictor of cancer with a corresponding hazard ratio (HR) of 2.90 (95% C.I. 1.44-5.83, p=0.003). A previous provoked VTE in patients was also associated with a higher risk of developing cancer (HR=3.57, 95% C.I. 1.38-9.25, p=0.009). Patients with an unprovoked deep vein thrombosis (DVT), compared to either those with a pulmonary embolism (PE) only or both DVT and PE, seemed more likely to have a diagnosis of cancer. However, this trend was not statistically significant. (Table 1) These results were confirmed on multivariable analysis. Patients exhibiting one of these characteristics had a three-fold higher risk of occult cancer compared with patients without these characteristics. (Table 1)
Conclusion: Age at unprovoked VTE diagnosis (≥ 60 years) and prior provoked VTE are predictors of occult cancer, and could potentially be used to identify a group of patients with unprovoked VTE at high risk of underlying cancer.
. | Patients without cancer (%) (n = 821) . | Patients with cancer (%) (n = 33) . | Univariate analysis Hazard Ratio (95% C.I.) . | P value . | Multivariable analysis Hazard Ratio (95% C.I.) . | P value . |
---|---|---|---|---|---|---|
Age at diagnosis ≥ 60 years | 288 (35.1) | 20 (60.6) | 2.90 (1.44-5.83) | 0.003 | 3.0 (1.47-5.99) | 0.002 |
Male sex | 555 (67.6) | 21 (63.6) | 0.72 (0.35-1.46) | 0.358 | - | - |
Prior provoked VTE | 42 (5.1) | 5 (15.2) | 3.57 (1.38-9.25) | 0.009 | 3.8 (1.46-10.03) | 0.006 |
Type of current VTE | ||||||
DVT only | 444 (54.3) | 24 (72.7) | 1.91 (0.89-4.12) | 0.097 | 2.1 (0.97-4.51) | 0.061 |
PE only | 271 (33.1) | 7 (21.2) | 0.60 (0.26-1.38) | 0.229 | - | - |
DVT + PE | 103 (12.6) | 2 (6.1) | 0.54 (0.13-2.24) | 0.392 | - | - |
Baseline medications | ||||||
Oral contraceptive pill | 48 (5.8) | 0 (0.0) | - | - | - | - |
Exogenous estrogen | 18 (2.2) | 1 (3.0) | 1.51 (0.21-11.07) | 0.685 | - | - |
Antiplatelet agent | 39 (4.8) | 1 (3.0) | 0.62 (0.09-4.56) | 0.641 | - | - |
Oral anticoagulant | 688 (83.8) | 26 (78.8) | 0.66 (0.29-1.53) | 0.337 | - | - |
LMWH | 391 (47.7) | 15 (45.5) | 0.68 (0.34-1.36) | 0.275 | - | - |
. | Patients without cancer (%) (n = 821) . | Patients with cancer (%) (n = 33) . | Univariate analysis Hazard Ratio (95% C.I.) . | P value . | Multivariable analysis Hazard Ratio (95% C.I.) . | P value . |
---|---|---|---|---|---|---|
Age at diagnosis ≥ 60 years | 288 (35.1) | 20 (60.6) | 2.90 (1.44-5.83) | 0.003 | 3.0 (1.47-5.99) | 0.002 |
Male sex | 555 (67.6) | 21 (63.6) | 0.72 (0.35-1.46) | 0.358 | - | - |
Prior provoked VTE | 42 (5.1) | 5 (15.2) | 3.57 (1.38-9.25) | 0.009 | 3.8 (1.46-10.03) | 0.006 |
Type of current VTE | ||||||
DVT only | 444 (54.3) | 24 (72.7) | 1.91 (0.89-4.12) | 0.097 | 2.1 (0.97-4.51) | 0.061 |
PE only | 271 (33.1) | 7 (21.2) | 0.60 (0.26-1.38) | 0.229 | - | - |
DVT + PE | 103 (12.6) | 2 (6.1) | 0.54 (0.13-2.24) | 0.392 | - | - |
Baseline medications | ||||||
Oral contraceptive pill | 48 (5.8) | 0 (0.0) | - | - | - | - |
Exogenous estrogen | 18 (2.2) | 1 (3.0) | 1.51 (0.21-11.07) | 0.685 | - | - |
Antiplatelet agent | 39 (4.8) | 1 (3.0) | 0.62 (0.09-4.56) | 0.641 | - | - |
Oral anticoagulant | 688 (83.8) | 26 (78.8) | 0.66 (0.29-1.53) | 0.337 | - | - |
LMWH | 391 (47.7) | 15 (45.5) | 0.68 (0.34-1.36) | 0.275 | - | - |
VTE, venous thromboembolism; DVT, deep vein thrombosis; PE, pulmonary embolism; LMWH, low molecular weight heparin
Lazo-Langner:Pfizer: Honoraria, Other: Participated in studies funded by this organization, Speakers Bureau; LEO Pharma: Honoraria, Other: Participated in studies funded by this organization; Boehringer Ingelheim: Honoraria, Other: Participated in studies funded by this organization; Bayer: Honoraria, Other: Participated in studies funded by this organization; Daiichi-Sankyo: Other: Participated in studies funded by this organization; Novartis: Other: Participated in studies funded by this organization; Celgene: Other: Participated in studies funded by this organization; Alexion: Research Funding. Shivakumar:Bayer: Honoraria. Routhier:Sanofi-Aventis: Research Funding. Douketis:Janssen: Consultancy; Bristol-Myers Squibb: Consultancy, Honoraria; Pfizer: Honoraria; Sanofi-Aventis: Honoraria; Daiichi-Sankyo: Consultancy; Actelion: Consultancy; Biotie: Other: Advisory board; The Medicines Company: Other: Advisory board; Bayer: Consultancy; Boehringer Ingelheim: Consultancy, Honoraria. Carrier:LEO Pharma: Consultancy, Research Funding; BMS: Research Funding; Bayer: Consultancy; Pfizer: Consultancy.
Author notes
Asterisk with author names denotes non-ASH members.
This icon denotes a clinically relevant abstract
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal